Perspective Therapeutics (CATX) announced that the first patient was treated with (212Pb)PSV359 in a Phase 1/2a dose-finding trial to determine safety and preliminary anti-tumor activity of the radiopharmaceutical(212Pb)PSV359 in patients with solid tumors that express fibroblast activation protein alpha. Patients are being selected for(212Pb)PSV359 targeted alpha particle therapy by SPECT imaging with (212Pb)PSV359.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CATX:
- Perspective Therapeutics management to meet with Truist
- Tax Day 2025 IRS Payment: Stocks to Consider Buying With the Refund
- Optimistic Buy Rating for Perspective Therapeutics Amid Strategic Clinical Developments and Strong Financial Position
- Perspective announces first patient dosed in Phase 1/2a trial of 212PbVMT01
- Perspective Therapeutics price target lowered to $10 from $21 at Truist